UA78699C2 - Use of bile acid or bile salt fatty acid conjugates for decreasing cholesterol blood content, treating fatty liver, hyperglycemia, and diabetes - Google Patents

Use of bile acid or bile salt fatty acid conjugates for decreasing cholesterol blood content, treating fatty liver, hyperglycemia, and diabetes Download PDF

Info

Publication number
UA78699C2
UA78699C2 UA2003109404A UA2003109404A UA78699C2 UA 78699 C2 UA78699 C2 UA 78699C2 UA 2003109404 A UA2003109404 A UA 2003109404A UA 2003109404 A UA2003109404 A UA 2003109404A UA 78699 C2 UA78699 C2 UA 78699C2
Authority
UA
Ukraine
Prior art keywords
acid
bile
animals
liver
diabetes
Prior art date
Application number
UA2003109404A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Galmed Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galmed Int Ltd filed Critical Galmed Int Ltd
Publication of UA78699C2 publication Critical patent/UA78699C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
UA2003109404A 2001-04-17 2002-04-15 Use of bile acid or bile salt fatty acid conjugates for decreasing cholesterol blood content, treating fatty liver, hyperglycemia, and diabetes UA78699C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL142650A IL142650A (en) 1998-04-08 2001-04-17 Use of bile acid or bile salt fatty acids conjugates for the preparation of pharmaceutical compositions for reducing cholesterol, treating fatty liver and treating hyperglycemia and diabetes
PCT/IL2002/000303 WO2002083147A1 (en) 2001-04-17 2002-04-15 Use of bile acid or bile salt fatty acid conjugates

Publications (1)

Publication Number Publication Date
UA78699C2 true UA78699C2 (en) 2007-04-25

Family

ID=11075322

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2003109404A UA78699C2 (en) 2001-04-17 2002-04-15 Use of bile acid or bile salt fatty acid conjugates for decreasing cholesterol blood content, treating fatty liver, hyperglycemia, and diabetes

Country Status (24)

Country Link
US (2) US7501403B2 (cg-RX-API-DMAC10.html)
EP (2) EP1379254B1 (cg-RX-API-DMAC10.html)
JP (1) JP4324706B2 (cg-RX-API-DMAC10.html)
KR (1) KR100883080B1 (cg-RX-API-DMAC10.html)
CN (1) CN1259918C (cg-RX-API-DMAC10.html)
AT (2) ATE365044T1 (cg-RX-API-DMAC10.html)
AU (2) AU2002307771B2 (cg-RX-API-DMAC10.html)
BR (1) BR0208924A (cg-RX-API-DMAC10.html)
CA (2) CA2444266C (cg-RX-API-DMAC10.html)
CY (1) CY1106853T1 (cg-RX-API-DMAC10.html)
CZ (2) CZ309042B6 (cg-RX-API-DMAC10.html)
DE (2) DE60232559D1 (cg-RX-API-DMAC10.html)
DK (2) DK1379254T3 (cg-RX-API-DMAC10.html)
EA (1) EA007565B1 (cg-RX-API-DMAC10.html)
ES (2) ES2289137T3 (cg-RX-API-DMAC10.html)
HU (1) HU230548B1 (cg-RX-API-DMAC10.html)
IL (1) IL142650A (cg-RX-API-DMAC10.html)
MX (1) MXPA03009553A (cg-RX-API-DMAC10.html)
NO (2) NO333910B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ528868A (cg-RX-API-DMAC10.html)
PL (2) PL205057B1 (cg-RX-API-DMAC10.html)
PT (2) PT1379254E (cg-RX-API-DMAC10.html)
UA (1) UA78699C2 (cg-RX-API-DMAC10.html)
WO (1) WO2002083147A1 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142650A (en) 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid or bile salt fatty acids conjugates for the preparation of pharmaceutical compositions for reducing cholesterol, treating fatty liver and treating hyperglycemia and diabetes
US8975246B2 (en) * 2001-04-17 2015-03-10 Galmed Research And Development Ltd. Bile acid or bile salt fatty acid conjugates
SI2182954T1 (sl) * 2007-07-25 2019-04-30 Medizinische Universitat Graz Uporaba nor-žolčnih kislin pri zdravljenju arterioskleroze
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
HUE034551T2 (en) * 2009-01-12 2018-02-28 Biokier Inc Composition and method for treatment of diabetes
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
US20120157419A1 (en) 2009-02-02 2012-06-21 Tuvia Gilat Methods and compositions for treating alzheimer's disease
US20120202890A1 (en) 2011-02-08 2012-08-09 Nian Wu Polymer-carbohydrate-lipid conjugates
EP2844257A4 (en) * 2012-05-01 2016-06-01 Catabasis Pharmaceuticals Inc Fatty Acid Conjugates from Statin and FXR Agonists; COMPOSITIONS AND METHODS OF USE
CN103571617A (zh) * 2012-07-26 2014-02-12 丰益(上海)生物技术研发中心有限公司 改进的动物油脂加工工艺
KR101702251B1 (ko) * 2012-11-29 2017-02-02 에스티팜 주식회사 신규한 소포 수송에 이용하기 위한 담즙산 올리고머 결합체 및 이의 용도
IL227890A0 (en) * 2013-08-08 2014-01-30 Galderm Therapeutics Ltd Antiaging compounds containing bile acid and fatty acid conjugates
WO2016199137A1 (en) * 2015-06-10 2016-12-15 Galmed Research And Development Ltd. Low dose compositions of aramchol salts
LT3077047T (lt) * 2013-12-04 2019-08-26 Galmed Research & Development Ltd. Aramcholio druskos
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
WO2015186126A1 (en) * 2014-06-01 2015-12-10 Galmed Research And Development Ltd. Fatty acid bile acid conjugates for treatment of lipodystrophy
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
CN116687850A (zh) 2022-02-24 2023-09-05 甘莱制药有限公司 包含环状膦酸酯化合物的药物组合物及其制备方法与用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859437A (en) * 1972-06-02 1975-01-07 Intellectual Property Dev Corp Reducing cholesterol levels
US3856953A (en) 1973-05-15 1974-12-24 Intellectual Property Dev Corp Method of treating fatty liver
IT1167478B (it) * 1981-07-24 1987-05-13 Carlo Scolastico Derivati dell'acido ursodesossicolico
IT1167479B (it) * 1981-07-24 1987-05-13 Carlo Scolastico Derivati dell'acido chenodesossicolico
JPS6164701A (ja) * 1984-09-06 1986-04-03 Meito Sangyo Kk カチオン化デキストラン誘導体とポリウロン酸の高分子電解質錯体及びその利用
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5278320A (en) 1992-09-11 1994-01-11 Merck & Co., Inc. Cholesterol lowering compounds produced by directed biosynthesis
DE4432708A1 (de) * 1994-09-14 1996-03-21 Hoechst Ag Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
KR20010031501A (ko) * 1997-10-31 2001-04-16 추후제출 5-알파 환원효소 활성을 조절하는 방법 및 조성물
IL123998A (en) * 1998-04-08 2004-09-27 Galmed Int Ltd Conjugates of bile salts and pharmaceutical preparations containing them
IL142650A (en) * 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid or bile salt fatty acids conjugates for the preparation of pharmaceutical compositions for reducing cholesterol, treating fatty liver and treating hyperglycemia and diabetes
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
JP2006306800A (ja) * 2005-04-28 2006-11-09 Kirin Brewery Co Ltd ファルネソイドx受容体活性化剤

Also Published As

Publication number Publication date
NZ528868A (en) 2005-09-30
PL366585A1 (en) 2005-02-07
CY1106853T1 (el) 2012-05-23
ES2289137T3 (es) 2008-02-01
NO333910B1 (no) 2013-10-14
ES2328966T3 (es) 2009-11-19
US20040121993A1 (en) 2004-06-24
NO20034609D0 (no) 2003-10-15
US8110564B2 (en) 2012-02-07
HU230548B1 (hu) 2016-11-28
CA2444266A1 (en) 2002-10-24
US7501403B2 (en) 2009-03-10
NO335087B1 (no) 2014-09-08
CA2703688A1 (en) 2002-10-24
EP1790346A2 (en) 2007-05-30
MXPA03009553A (es) 2004-05-24
PT1790346E (pt) 2009-09-04
CA2703688C (en) 2012-07-31
KR20030092063A (ko) 2003-12-03
KR100883080B1 (ko) 2009-02-10
BR0208924A (pt) 2004-04-20
JP2004525962A (ja) 2004-08-26
HUP0400801A2 (hu) 2004-08-30
IL142650A0 (en) 2002-03-10
EP1379254B1 (en) 2007-06-20
AU2007200191A1 (en) 2007-02-08
HUP0400801A3 (en) 2012-09-28
NO20034609L (no) 2003-11-28
EP1379254A1 (en) 2004-01-14
PL211438B1 (pl) 2012-05-31
WO2002083147A1 (en) 2002-10-24
CZ20032710A3 (cs) 2004-04-14
PT1379254E (pt) 2007-07-10
AU2007200191B2 (en) 2008-09-04
EP1790346A3 (en) 2007-08-22
PL205057B1 (pl) 2010-03-31
CZ2008296A3 (cg-RX-API-DMAC10.html) 2004-04-14
ATE365044T1 (de) 2007-07-15
NO20131219L (no) 2003-11-28
ATE432705T1 (de) 2009-06-15
CZ309042B6 (cs) 2021-12-22
EA007565B1 (ru) 2006-12-29
EA200301017A1 (ru) 2005-04-28
DK1790346T3 (da) 2009-10-12
CN1259918C (zh) 2006-06-21
JP4324706B2 (ja) 2009-09-02
IL142650A (en) 2007-06-03
DE60232559D1 (de) 2009-07-16
US20090149537A1 (en) 2009-06-11
DE60220775D1 (de) 2007-08-02
EP1790346B1 (en) 2009-06-03
CN1529603A (zh) 2004-09-15
DK1379254T3 (da) 2007-10-15
CA2444266C (en) 2010-07-27
CZ300489B6 (cs) 2009-06-03
AU2002307771B2 (en) 2006-10-19
DE60220775T2 (de) 2008-03-06

Similar Documents

Publication Publication Date Title
AU2007200191B2 (en) Use of bile acid or bile salt fatty acid conjugates
Okediran et al. Alterations in the lipid profile and liver enzymes of rats treated with monosodium glutamate.
CZ2003535A3 (cs) Potravinářský prostředek
WO2008066308A1 (en) Food composition for increasing the satiety and satiation
CZ24999A3 (cs) Farmaceutický prostředek
JP2009533342A (ja) シトルリンを使用する治療
JP2015530412A (ja) カルシウムβ−ヒドロキシ−β−メチルブチレート、タンパク質および低レベルの電解質を含む栄養組成物
CN113924089A (zh) 使用一种或多种自噬诱发氨基酸来增强一种或多种合成代谢氨基酸的肌肉骨骼效应的组合物和方法
Jangra et al. Ameliorative effect of fermentable fibres on adiposity and insulin resistance in C57BL/6 mice fed a high-fat and sucrose diet
WO1999021566A1 (en) Dietary composition with lipid binding properties for weight management and serum lipid reduction
CN103861086A (zh) 一种苦瓜肽阿拉伯糖复合片的制作方法
CN113924120A (zh) 增强一种或多种合成代谢氨基酸的肌肉骨骼效应的组合物和方法
DK2266619T3 (en) PHARMACEUTICAL PREPARATION BASED ON A LIVING PROTECTIVE AGENT AND A PREBIOTIC AGENT, PREPARATION AND USE OF IT
CN105935364B (zh) 用于预防或治疗非酒精性肝病的包含人参皂苷f2的组合物
JP2006191830A (ja) 脂肪の蓄積を抑制する食品
Hokmabadinazhad et al. Bioactivity of mackerel peptides on obesity and insulin resistance, an in-vivo study
CN116546981A (zh) 使用至少一种甘氨酸或其衍生物和/或至少一种n-乙酰半胱氨酸或其衍生物以及至少一种百里酚和/或香芹酚的组合物和方法
JP4958339B2 (ja) 脂質代謝改善剤
CN114144189A (zh) 包含二甲基硅油和蔗糖酯的组合物及其作为消泡剂的用途
US7052722B2 (en) Composition for weight reduction comprising water-soluble low-molecular weight chitosan and Hibiscus extract
CN110710600A (zh) 一种肾衰宠物犬用的营养膏及其制备方法
JP2005021097A (ja) ダイエット食品
Dakam et al. Effects of sodium bicarbonate and albumin on the in vitro water-holding capacity and some physiological properties of Trigonella foenum graecum L. galactomannan in rats
JP3521067B2 (ja) 大腸菌感染防止剤
JPH05320058A (ja) ヒアルロン酸含有血中脂質低下剤